**ABSTRACT**

Fibromatosis are rare, accounting for 0.03% of all tumours. Mesenteric fibromatosis is a very rare (8% of all desmoid neoplasm). Aggressive fibromatosis is rare, due to surgical problem affecting 2-4 per million people. Females are more commonly affected than males (Estrogen acts as a growth factor). It is locally invasive and tends to recur but never metastasize. Here, we are discussing about 24-year-old male presented with progressive abdomen distension associated with pain since one month. Abdominal examination showed a firm non-tender intra-abdominal mass, measuring around 15x14 cm size, with intrinsic mobility, which was peripheric to mesenteric line, all borders were well-made out. CECT abdomen showed features suggestive of GIST. Elective Laparotomy was done and a giant mass arising from mesentery without any infiltration to the surrounding structures was noted. The entire mass was excised and mesentery repaired. Histopathology showed uniform band of spindle shaped cells arranged in fascicles admixed with blood vessels in a collagenous stroma. Immunohistochemistry showed Beta Catenin +ve, CD 117-ve, CD 34 –ve and SMA-ve, which is confirmative of Fibromatosis. Postoperative period was uneventful.

**CASE REPORT**

A 24-year-old male presented with progressive abdomen distention associated with pain since one month. No history of previous abdominal surgery, intestinal polyposis. Abdominal examination showed a firm non-tender intra-abdominal mass, measuring around 15x14 cm size, with intrinsic mobility, mass mobile peripheric to the mesenteric line, all borders were well made out. A clinical diagnosis of mass arising from mesentery was made. Contrast enhanced CT scan (CECT) abdomen showed features suggestive of Gastrointestinal stromal tumour (GIST). A large well-defined intra-abdominal mass measuring 16.4x15.2x10.6 cm extending from L2-L5 to posterior part of abdominal wall was noted. Post contrast enhancement was noted with central nonenhancing necrotic areas without any calcification. Differential diagnosis is GIST and Mesentery tumour. ESR, complete hemogram, Liver function test and Renal function test are normal. Elective laparotomy was done and a giant mass arising from mesentery without any infiltration to the surrounding structures was noted. The Entire mass was excised and mesentery repaired. Histopathology showed uniform band of spindle shaped cells arranged in fascicles admixed with blood vessels in a collagenous stroma. Cells are infiltrating skeletal muscle without necrosis and mitosis. Immunohistochemistry showed Beta Catenin +ve, CD 117-ve, CD 34 –ve and SMA-ve, which is confirmative of Fibromatosis (Desmoid tumour) and mesenteric fibromatosis. Postoperative period was uneventful.

**DISCUSSION**

Desmoid tumours (Fibromatosis) derived from the Greek word desmos which means ‘band of tendons’. They arise due to fibroblast cell mutations (APC and Beta Catenin). Fibromatosis are rare, accounting for 0.03% of all tumours [1] with incidence rate of 2-4 per million. Females are more commonly affected than males (Estrogen acts as a growth factor). Fibromatosis affect both superficial and deep parts of the body. Superficial fibromatosis involves the face and neck (fibromatosis coli), palms (Dupuytren's contracture), feet (Ledderhose's disease), penis (Peyronie's disease), shoulder, thigh, buttock and trunk. Deep fibromatosis are divided into abdominal, extra-abdominal (desmoids outside the abdominal wall) and intraabdominal types. Mesenteric fibromatosis is very rare (8% of all desmoid neoplasm) intra abdominal benign fibrous lesion which usually involves the small bowel mesentery, locally invasive, tends to recur but never metastasize. Its biological behavior is intermediate between benign fibrous lesions and fibrosarcoma. Koh et al., classified mesenteric fibromatosis into five categories based on clinical course: (1) spontaneous regression; (2) stable; (3) variable growth; (4) progressive growth; and (5) aggressive growth [2]. The exact etiopathogenesis of mesenteric fibromatosis is unknown; but various associated factors are (a) Trauma, (b) Estrogen as a growth factor (c) Garden Syndrome (d) Crohn's disease. Most are asymptomatic, but few present with abdominal mass, abdominal pain, fatigue, vomiting. Mesenteric desmoid infiltrates adjacent organs and cause important complications like intestinal obstruction, ischemia and perforation, hydronephrosis, ureteric fistula and even aortic rupture [3,4]. Microscopically, mesenteric fibromatosis is characterized by a spatially homogenous proliferation of wavy spindle cells without atypia, associated with collagen among dilated vessels. The mitotic count is relatively low with no evidence of necrosis and nuclear dedifferentiation [5]. Important differential diagnoses for mesenteric fibromatosis are GIST and Sclerosing Fibromatosis. Immunohistochemistry (IHC) shows diffuse nuclear positivity for Beta-catenin in Mesenteric fibromatosis but not in GIST and Sclerosis fibromatosis. USG and CECT scan are imaging modalities commonly used to diagnose mesenteric fibromatosis.

Treatment of choice is complete excision. Radiotherapy can be used in recurrences and to shrink the inoperable tumours. In cases where surgery and radiotherapy are unsuccessful pharmacotherapy may be used. Pharmacotherapy in desmoid tumour involves 1. Non cytotoxic drugs NSAIDS (Sulindac, Indomethacin) 2. Endocrine therapy (estrogen receptor antagonist tamoxifen, Aromataze inactivators) 3. Cytotoxic chemotherapy (dactinomycin, vincristine and cyclophosphamide) [7]. TeikYin co-researchers [8] demonstrated the resolution of hydronephrosis due to massive mesenteric fibromatosis by using cyclo-oxygenase 2 inhibitors. Tonelli et al., [9] reported that the daily use of raloxifene decreased mesenteric fibromatosis size without significant side effects. Chemotherapy may be used in : (i) aggressive surgical resections which could result in severe disfigurement especially in young patients (eg: limb-sacrificing surgical procedures, hemimandibullectomies, hemipelvetomies, or chest wall resections). (ii) Large tumors (mesenteric or retroperitoneal) encasing vital structures such as vessels, nerves or ureters. (iii) Tumours which recur after use of other
non-cytotoxic treatment such as hormonal agents or NSAIDs. It has 25-50% chances of recurrence despite of above treatments [10].

CONCLUSION
Mesenteric Fibromatosis is rare problem. It can grow aggressively and attain large size as in this case within short span of time. Many times it will be confused with GIST. Different treatments available for mesenteric fibromatosis but surgery is the best.

REFERENCES